对接受华法林治疗的患者服用免疫检查点抑制剂可能会提高PT-INR
Kazuya Uenoyama1,2, Masahide Onoue1, Toshiro Katayama3
1Department of Pharmacy, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
|January 5, 2025
概括
同时使用免疫检查点抑制剂 (ICI) 与华法林可以提高前热血素时间-国际正常化比率 (PT-INR). 这项研究发现,两种疗法中超过一半的患者经历了显著的PT-INR升高,突出了严格监测的必要性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 免疫检查点抑制剂 (ICI) 正在彻底改变癌症治疗.
- 华法林是一种常见的抗凝剂,用于预防血栓形成.
- ICI和华法林之间的相互作用,特别是关于PT-INR水平的相互作用,尚不清楚.
研究的目的:
- 在接受免疫检查点抑制剂 (ICI) 和华法林治疗的患者中,研究高血时间-国际正常化比率 (PT-INR) 的发生率和严重程度.
- 在这个患者群体中评估PT-INR升高的临床影响.
主要方法:
- 对26名同时接受ICI和华法林治疗的患者进行了回顾性分析.
- 在ICI给药后60天内监测PT-INR水平.
- 关于PT-INR升高严重程度和管理干预措施的文档.
主要成果:
- 26名患者中有13名 (50%) 患有2级或更高的PT-INR升高.
- 由于PT-INR升高,五名患者需要立即给予维生素K.
- 观察到与免疫相关的不良事件和PT-INR增加之间的潜在联系.
结论:
- 同时使用ICI和华法林与升高PT-INR的显著风险有关.
- 接受这两种疗法的患者需要对血液凝固能力进行警监测.
- 管理策略应考虑可能增加出血风险和对癌症治疗延续的影响.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
981
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
981
Anticoagulant Drugs: Low-Molecular-Weight Heparins
528
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
528
Therapeutic Index
3.9K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
3.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
384
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
384
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
89
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
89


